As part of our integrated Pharmaceutical Development & Manufacturing offering, we deliver end-to-end solutions within Drug Substance Development for protein therapeutics. Here, we focus on Therapeutic Protein Development, specifically hormone proteins, with services centered on laboratory biotechnology, robust analytics, and manufacturability for subsequent scale-up.
Overview of Hormone Protein Development
Hormone proteins span short synthetic peptides and complex recombinant glycoproteins. Their development requires careful modality selection (solid-phase peptide synthesis versus recombinant expression), tailored upstream and downstream processes, and stability-aware formulations to preserve bioactivity. For heterodimeric glycoproteins, precise subunit expression and glycan control are crucial; for smaller peptide hormones, impurity profiling, aggregation control, and degradation pathway mapping drive quality. And, across all modalities, potency-relevant in-vitro assays, orthogonal structural analytics, and stress-tested formulations anchor a development package that is coherent, reproducible, and compatible with later manufacturing. Our workstream is deliberately positioned in pharmaceutical R&D, emphasizing platformable methods, clear specifications, and data that de-risk progression.
Our Services
Our services span modality strategy, cell line and process development, purification and analytics, and potency-linked bioassays—each designed for laboratory execution with clear handover packages.
Modality & Expression Strategy Service
We evaluate whether a target hormone is best advanced via SPPS (for short peptides/analogs) or recombinant systems (E. coli, yeast, or mammalian for larger or glycosylated hormones). We define expression constructs, secretion signals, and tags where appropriate, and map a development plan that anticipates purification and release testing.
Cell Line & Upstream Development Service
For recombinant hormones and glycoproteins, we design stable cell lines or optimized microbial strains, establish media/feed strategies, and build scale-down models. Design-of-experiments (DoE) accelerates definition of critical parameters (e.g., temperature, pH, feed profiles), while in-process analytics monitor titer, product quality attributes (PQAs), and relevant post-translational features.
Purification & Heterogeneity Control Service
We construct multistep downstream trains tailored to the modality: RP/ION-exchange and HIC options for peptides; capture/intermediate/polish sequences for recombinant forms. For heterodimeric hormones, we include subunit balance and assembly controls. Moreovre, we characterize and mitigate process-related impurities, truncations, isoforms, and charge variants, establishing scalable, orthogonal purification strategies with defined in-process acceptance criteria.
Analytical Characterization & Specification Setting Service
We develop identity, purity, and structural panels using orthogonal methods: intact mass, peptide mapping, disulfide verification, glycan profiling (where relevant), circular dichroism/DSC for higher-order structure, and size/charge analytics for heterogeneity.
Potency & Mechanism-Indicative Bioassay Service
We design cell-based or biochemical assays that reflect intended receptor engagement and downstream signaling, selecting systems that are robust for routine use. Assays are optimized for dynamic range, precision, and interference resistance, with bridging to surrogate readouts when helpful. The outcome is a potency framework aligned to PQAs and stability studies, enabling coherent control of bioactivity.
We provide laboratory-anchored, specification-driven development for hormone proteins, unifying modality strategy, upstream/downstream design, analytics, and potency. Our platformable methods de-risk later phases. Contact us to initiate a focused development plan.
Frequently Asked Questions
Q1: What are the unique challenges of heterodimeric glycoprotein hormones (FSH, LH, hCG)?
They require coordinated expression of α/β subunits, correct assembly, and glycan quality. Our approach uses dual-vector or bicistronic designs, subunit ratio tuning, and glycan profiling. Purification incorporates subunit-specific capture, assembly verification, and polish steps that reduce mis-paired or under-glycosylated species, supported by potency assays aligned to receptor activity.
Q2: What stability risks most often limit hormone protein progress, and how are they managed?
For peptides, hydrolysis, oxidation, isomerization, and aggregation are common; for larger proteins, deamidation and higher-order structure loss also arise. We map degradation via forced studies, use antioxidants or pH/ionic adjustments as appropriate, and design excipient systems that minimize adsorption and self-association. Shipping and handling stresses are simulated in scale-down models to set protective limits.
Our products and services are for research use only.
